This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2000 Oct:18 Suppl:IT18-20.

Cancer multidrug resistance

No authors listed

PMID: 11221708

Review

Cancer multidrug resistance

No authors listed. Nat Biotechnol. 2000 Oct.

. 2000 Oct:18 Suppl:IT18-20.

PMID: 11221708

No abstract available

PubMed Disclaimer

Similar articles

New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J, Mucsi I, Nacsa J, Hevér A, Gyémánt N, Ugocsai K, Hegyes P, Kiessig S, Gaal D, Lage H, Varga A. Molnar J, et al. Anticancer Res. 2004 Mar-Apr;24(2B):865-71. Anticancer Res. 2004. PMID: 15161039
Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges.
Zhang D, Fan D. Zhang D, et al. Expert Rev Anticancer Ther. 2007 Oct;7(10):1369-78. doi: 10.1586/14737140.7.10.1369. Expert Rev Anticancer Ther. 2007. PMID: 17944563 Review.
Drug development in the Pacific Rim.
Wong J. Wong J. Clin Adv Hematol Oncol. 2006 Sep;4(9):670-2. Clin Adv Hematol Oncol. 2006. PMID: 17099623 No abstract available.
Modulation of multidrug resistance and apoptosis of cancer cells by selected carotenoids.
Molnár J, Gyémánt N, Mucsi I, Molnár A, Szabó M, Körtvélyesi T, Varga A, Molnár P, Tóth G. Molnár J, et al. In Vivo. 2004 Mar-Apr;18(2):237-44. In Vivo. 2004. PMID: 15113052
Multidrug resistance in hematological malignancy.
Hirose M, Hosoi E, Hamano S, Jalili A. Hirose M, et al. J Med Invest. 2003 Aug;50(3-4):126-35. J Med Invest. 2003. PMID: 13678381 Review.

See all similar articles

Cited by

Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.
Creixell M, Peppas NA. Creixell M, et al. Nano Today. 2012 Aug 1;7(4):367-379. doi: 10.1016/j.nantod.2012.06.013. Nano Today. 2012. PMID: 26257819 Free PMC article.
Combination of Chemotherapy and Mild Hyperthermia Using Targeted Nanoparticles: A Potential Treatment Modality for Breast Cancer.
Kaur I, Tieu T, Deepagan VG, Ali MA, Alsunaydih F, Rudd D, Moghaddam MA, Bourgeois L, Adams TE, Thurecht KJ, Yuce M, Cifuentes-Rius A, Voelcker NH. Kaur I, et al. Pharmaceutics. 2023 Apr 30;15(5):1389. doi: 10.3390/pharmaceutics15051389. Pharmaceutics. 2023. PMID: 37242631 Free PMC article.
Antitumor Activity of Pulvomycin via Targeting Activated-STAT3 Signaling in Docetaxel-Resistant Triple-Negative Breast Cancer Cells.
Byun WS, Bae ES, Cui J, Park HJ, Oh DC, Lee SK. Byun WS, et al. Biomedicines. 2021 Apr 17;9(4):436. doi: 10.3390/biomedicines9040436. Biomedicines. 2021. PMID: 33920736 Free PMC article.
Local dose-dense chemotherapy for triple-negative breast cancer via minimally invasive implantation of 3D printed devices.
Myung N, Kang HW. Myung N, et al. Asian J Pharm Sci. 2024 Feb;19(1):100884. doi: 10.1016/j.ajps.2024.100884. Epub 2024 Jan 12. Asian J Pharm Sci. 2024. PMID: 38357526 Free PMC article.
Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents.
Dhuguru J, Ghoneim OA. Dhuguru J, et al. Molecules. 2022 Mar 31;27(7):2294. doi: 10.3390/molecules27072294. Molecules. 2022. PMID: 35408693 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database